Loading clinical trials...
Loading clinical trials...
Phase II Study Evaluating Pomegranate Juice In Patients With Recurrent Adenocarcinoma Of The Prostate
RATIONALE: Pomegranate juice may contain substances that decrease or slow the rise of prostate-specific antigen (PSA) levels and may be effective in delaying or preventing recurrent prostate cancer. PURPOSE: This phase II trial is studying how well pomegranate juice works in decreasing or slowing the rise of PSA levels in patients who have undergone radiation therapy or surgery for prostate cancer.
OBJECTIVES: * Determine whether pomegranate juice can decrease or slow rising prostate-specific antigen (PSA) levels in patients who have undergone radical prostatectomy or radiotherapy for adenocarcinoma of the prostate. OUTLINE: Patients receive oral pomegranate juice once daily. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 29-40 patients will be accrued for this study.
Age
18 - No limit years
Sex
MALE
Healthy Volunteers
No
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California, United States
Start Date
November 30, 2004
Primary Completion Date
May 25, 2021
Completion Date
May 25, 2021
Last Updated
June 4, 2021
47
ACTUAL participants
pomegranate juice
DIETARY_SUPPLEMENT
Lead Sponsor
Jonsson Comprehensive Cancer Center
Collaborators
NCT05691465
NCT04550494
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions